These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35870900)

  • 1. Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.
    Martinez A; Chantalat E; Angeles MA; Ferron G; Ducassou A; Daix M; Attal J; Bétrian S; Lusque A; Gabiache E
    BMC Cancer; 2022 Jul; 22(1):810. PubMed ID: 35870900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer.
    Martinez A; Voglimacci M; Lusque A; Ducassou A; Gladieff L; Dupuis N; Angeles MA; Martinez C; Tanguy Le Gac Y; Chantalat E; Hitzel A; Courbon F; Ferron G; Gabiache E
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1252-1260. PubMed ID: 31915897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
    Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
    Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
    Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Leray H; Gabiache E; Courbon F; Brenot-Rossi I; Colineaux H; Lepage B; Lambaudie E; Martinez A; Voglimacci M; Weyl A; Deslandres M; Ducassou A; Motton S; Vaysse C; Chantalat E
    J Nucl Med; 2020 Oct; 61(10):1442-1447. PubMed ID: 32034109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic parameters of [
    Markus M; Sartor H; Bjurberg M; Trägårdh E
    Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
    Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
    Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
    Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
    PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer.
    De Cuypere M; Lovinfosse P; Gennigens C; Hermesse J; Rovira R; Duch J; Goffin F; Hustinx R; Kridelka F
    Int J Gynecol Cancer; 2020 Nov; 30(11):1705-1712. PubMed ID: 33033165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
    Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (
    Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
    Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Guler OC; Reyhan M; Yapar AF
    Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
    Guler OC; Torun N; Yildirim BA; Onal C
    Br J Radiol; 2018 Apr; 91(1084):20170552. PubMed ID: 29293366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added value of para-aortic surgical staging compared to
    De Cuypere M; Lovinfosse P; Goffin F; Gennigens C; Rovira R; Duch J; Fastrez M; Gebhart G; Squifflet JL; Luyckx M; Charaf G; Crener K; Buxant F; Bucella D; Jouret M; Hustinx R; Kridelka F
    Eur J Surg Oncol; 2020 May; 46(5):883-887. PubMed ID: 31784203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term assessment of clinical parameters and positron emission tomography parameters in predicting recurrence in uterine cervical cancer patients receiving definitive chemoradiotherapy.
    Onal C; Guler OC; Torun N; Reyhan M
    Nucl Med Commun; 2024 Mar; 45(3):203-210. PubMed ID: 38165168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
    Yilmaz B; Dağ S; Ergul N; Çermik TF
    Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
    Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
    Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.